SMTL ID : 7n4q.1

Bruton's tyrosine kinase in complex with compound 45

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.50 Å

Oligo State

monomer

Ligands

1 x 0B9: (2R)-2-(3-chloro-5-fluoroanilino)-2-cyclopropyl-N-[(3R)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl]acetamide(Non-covalent)

0B9.1: 18 residues within 4Å: Chain A: L.18, G.19, F.23, G.24, V.25, V.26, A.38, K.40, I.82, T.84, E.85, Y.86, M.87, R.135, N.136, L.138, D.149, L.152 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:L.18, A:F.23, A:V.26, A:L.138, A:L.152 Hydrogen bonds: A:K.40, A:T.84, A:E.85, A:M.87, A:D.149

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Hopkins, B.T. et al., Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors. Bioorg.Med.Chem. (2021)

Release Date

2022-05-18

Peptides

Tyrosine-protein kinase BTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase BTK

Related Entries With Identical Sequence